Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISCOVER-2 hypofractionated vs conventional chemoradiotherapy plus durvalumab in unresectable stage III NSCLC
ChiCTR2400080122Phase 3Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Feb 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of durvalumab, paclitaxel, cisplatin and carboplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: overall survival and progression-free survival. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
durvalumabpaclitaxelcisplatincarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400080122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080122.